Thursday, May 26, 2011

6 key drives that have propelled Genentech to the top reputation in oncology

In one recent study of company reputation in oncology, Genentech occupied a tier of its own, with a significant lead over second-tier companies Novartis, Amgen, Eli Lilly, Pfizer, and Sanofi-Aventis.  Third-tier includes Takeda/Millennium, Celgene, GSK, AstraZeneca, Bristol-Myers Squibb, and Roche. The fourth-tier companies were Bayer Healthcare, Eisai, and J&J.

Genentech’s strong performance on the key driver attributes (those measures that are most important in driving perceptions of overall company performance) is responsible for propelling it into the top spot. In fact, Genentech ranks first on all six key driver attributes, with a significant lead over all other companies on all but one of the six.

The six key drivers are:
  1. The company is developing beneficial products
  2. The company shows increasing strength in oncology
  3. The company has an innovative R&D
  4. A company that I can trust
  5. Sales reps respect a physician’s time
  6. Sales reps are knowledgeable about a company’s products

No comments: